Methotrexate (MTX), a cellular DHFR inhibitor, can suppress the entry and replication of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for COVID-19, by targeting furin and the host DHFR enzyme, respectively. This evidence concerns the gene DHFR and COVID-19.